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Beyond X-Chromosome Inactivation: The Oncogenic Facet of 
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Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea 
Long-non coding RNAs (LncRNAs) constitute a wide and extremely diverse family of RNA transcripts that are greater 
than 200 base pairs in length and are not translated into proteins. X-inactive specific transcript (XIST) was the first long 
non-coding RNA to be discovered, back in 1991. Its function in X-chromosome inactivation has been extensively studied 
for three decades, though other functional roles of XIST that involve a variety of fascinating mechanisms remain to be 
elucidated. Here, we review the emerging oncogenic role of XIST in various human cancers. 
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INTRODUCTION 
 
The specific transcript involved in X chromosome in- 
activation is called X-inactive specific transcript (XIST), 
and it was the first long non-coding RNA to be identified, 
by Brown et al. in 1991. XIST is thought to be a critical 
determinant for X chromosome inactivation. It is a 17,000- 
base-pair long non-coding RNA (lncRNA) that is spliced, 
polyadenylated, and constrained to the nucleus, and it does 
not produce a protein product. 
A recent round of studies has provided new evidence of 
an oncogenic role of XIST in several cancers (Fig. 1). XIST 
has been shown to be highly expressed in tumor tissues 
compared to normal tissues. Furthermore, many reports have 
underlined its clinical significance and suggested that XIST 
can serve as a prognostic marker for many tumors. Mechan- 
istically, XIST exerts its oncogenic effects by acting mainly 
as a competing endogenous RNA (ceRNA); the mechanism 
of ceRNAs is a relatively new epigenetic concept, which 
suggests that a competition might exist between a micro- 
RNA (miRNA) and a lncRNA leading to the upregulation 
of a target gene (Thomson and Dinger, 2016). In fact, XIST 
seems to act as a sponge for a plethora of miRNAs in various 
tumors. As the ceRNA concept provides new insights and 
indicates a more sophisticated post-transcriptional gene regu- 
lation role of XIST, via miRNA sequestration, deciphering 
the newly emerging function of XIST is needed now more 
than ever. 
This review provides an overview of the auspicious sponge 
role of XIST in cancer, as summarized in Table 1. 
Lung cancer 
Recent studies have consolidated previous findings estab- 
lishing a correlation between the XIST lncRNA and lung 
cancer, where XIST has been proven to be very important 
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Table 1. Functional characterization of XIST in human cancers 
 Cancer type 
 
 
XIST 
expression 
level 
XIST molecular 
target (s) 
 
Downstream 
genes 
 
Effect on cancer 
progression and 
metastasis 
Functional role of 
XIST (oncogene/ 
tumor suppressor) 
References 
 
 
Non-small-cell 
lung cancer 
Upregulated 
 
miR-367 and 
miR-141 
ZEB2 
 
⬆ TGF-β induced 
EMT 
Oncogene 
 
Li et al., 2018 
 
Upregulated 
 
miR-137 
 
PXN/Notch-1 
 
⬆ Proliferation 
⬆ Invasion 
Oncogene 
 
Jiang et al., 2018 
Wang et al., 2018 
Upregulated 
 
 
miR-186-5p 
 
 
Unknown 
 
 
⬆ Cell viability 
⬆ Invasion 
⬇ Apoptosis 
Oncogene 
 
 
Wang et al., 2017a 
 
 
Upregulated 
 
 
 
miR-449a 
 
 
 
Bcl-2 
 
 
 
⬆ Cell proliferation 
⬆ Cell migration and 
invasion 
⬇ Apoptosis 
Oncogene 
 
 
 
Zhang et al., 2017 
 
 
 
Upregulated 
 
 
 
miR-374a 
 
 
 
LARP1 
 
 
 
⬆ Cell growth 
⬆ Migration 
⬆ Invasion 
⬆ Tumorigenicity 
Oncogene 
 
 
 
Xu et al., 2017b 
 
 
 
Upregulated 
 
 
 
 
EZH2 
 
 
 
 
KLF2 
 
 
 
 
⬆ Cell proliferation 
⬆ Migration 
⬆ Invasion 
⬆ Tumorigenicity 
Poor prognosis 
Oncogene 
 
 
 
 
Fang et al., 2016 
 
 
 
 
Upregulated 
 
 
miR-17 
 
 
ATG7 
 
 
⬆ Autophagy 
⬆ TNM stage 
⬆ Chemoresistance 
Oncogene 
 
 
Sun et al., 2017b 
 
 
Upregulated 
 
Let-7i 
 
BAG-1 
 
⬆ Resistance to  
cisplatin 
Oncogene 
 
Sun et al., 2017a 
 
Upregulated 
 
 
miR-140 
 
 
iASPP 
 
 
⬆ Cell proliferation 
⬇ Apoptosis 
⬆ Metastasis 
Oncogene 
 
 
Tang et al., 2017 
 
 
Colorectal and 
Gastric cancer 
Upregulated 
 
miR-185 
 
TGF-β1 
 
⬆ Cell growth 
⬆ GC progression 
Oncogene 
 
Zhang et al., 2018 
 
Upregulated 
 
miR-34a 
 
WNT1/ 
β-catenin 
⬆ Cell proliferation 
⬆ Invasion 
Oncogene 
 
Sun et al., 2018a 
 
Upregulated 
 
miR-137 
 
EZH2 
 
⬆ EMT 
⬆ Invasion 
Oncogene 
 
Liu et al., 2018a 
 
Upregulated 
 
 
miR-497 
 
 
MACC1 
 
 
⬆ Cell cycle 
progression 
⬆ Invasion 
Oncogene 
 
 
Ma et al., 2017b 
 
 
Upregulated 
 
 
 
 
miR-200b-3p 
 
 
 
 
ZEB1 
 
 
 
 
⬆ Cell proliferation 
⬆ Invasion 
⬆ EMT 
⬆ Stemness 
⬇ Overall survival 
Oncogene 
 
 
 
 
Chen et al., 2017 
 
 
 
 
Upregulated 
 
miR-132-3p 
 
MAPK1 
 
⬆ Cell cycle 
progression 
Oncogene 
 
Song et al., 2017 
 
Upregulated 
 
 
Unknown 
 
 
TS 
 
 
⬇ 5-FU cytotoxicity 
Poor therapeutic 
efficacy 
Oncogene 
 
 
Xiao et al., 2017 
 
 
Upregulation 
 
 
miR-101 
 
 
EZH2 
 
 
⬆ Tumor 
aggressiveness 
Poor patient survival 
Oncogene 
 
 
Chen et al., 2016 
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Table 1. Functional characterization of XIST in human cancers (Continued) 
 Cancer type 
 
 
XIST 
expression 
level 
XIST molecular 
target (s) 
 
Downstream 
genes 
 
Effect on cancer 
progression and 
metastasis 
Functional role of 
XIST (oncogene/ 
tumor suppressor) 
References 
 
 
Hepatic 
cancer 
Upregulated 
 
 
miR-194-5p 
 
 
MAPK1 
 
 
⬆ Cell proliferation 
⬆ Migrasion 
⬆ Invation 
Oncogene 
 
 
Kong et al., 2018 
 
 
Downregulated 
 
miR-181a 
 
PTEN 
 
⬇ Cell proliferation 
⬇ Invasion 
Tumor suppressor 
 
Chang et al., 2017 
 
Upregulated 
 
 
miR-139-5p 
 
 
PDK1 
 
 
⬆ Cell cycle 
progression 
⬇ Apoptosis 
Oncogene 
 
 
Mo et al., 2017 
 
 
Downregulated 
 
miR-92b 
 
Smad7 
 
⬇ Cell proliferation 
⬇ Metastasis 
Tumor suppressor 
 
Zhuang et al., 2016 
 
Breast 
cancer 
Downregulated 
 
 
miR-155 
 
 
CDX1 
 
 
⬇ Cell growth 
⬇ Migration 
⬇ Invasion 
Tumor suppressor 
 
 
Zheng et al., 2018 
 
 
Downregulated PHLPP1 AKT ⬇ Cell viability Tumor suppressor Huang et al., 2016 
Glioma 
Upregulated 
 
miR-137 
 
Rac1 
 
⬆ Cell proliferation 
⬆ Tumorigenesis 
Oncogene 
 
Wang et al., 2017b 
 
Upregulated 
 
miR-29c 
 
MSH6/SP1/ 
MGMT 
⬆ Chemoresistance to 
TMZ 
Oncogene 
 
Du et al., 2017 
 
Upregulated 
 
 
miR-137 
 
 
FOXC1/ZO-2 
 
 
⬆ Angiogenesis 
⬇ Blood-tumor 
permeability 
Oncogene 
 
 
Yu et al., 2017 
 
 
Upregulated 
 
 
miR-429 
 
 
Unknown 
 
 
⬆ Tumorigenicity 
⬆ Angiogenesis 
⬆ Metastasis 
Oncogene 
 
 
Cheng et al., 2017 
 
 
Upregulated 
 
 
 
miR-152 
 
 
 
KLF4 
 
 
 
⬆ Cell proliferation 
⬆ Migration 
⬆ Invasion 
⬇ Stemness 
Oncogene 
 
 
 
Yao et al., 2015 
 
 
 
Pancreatic 
cancer 
Upregulated 
 
 
 
miR-34a-5p 
 
 
 
Unknown 
 
 
 
⬆ Cell proliferation 
⬆ Migration 
⬆ Invasion 
⬇ Apoptosis 
Oncogene 
 
 
 
Sun et al., 2018a 
 
 
 
Upregulated 
 
miR-133a 
 
EGFR 
 
⬆ Cell proliferation 
⬇ Poor prognosis 
Oncogene 
 
Wei et al., 2017 
 
Upregulated 
 
 
 
 
 
miR-140/ 
miR-124 
 
 
 
 
iASPP 
 
 
 
 
 
⬆ Cell cycle 
progression 
⬆ Cell proliferation 
Poor 
clinicopathological 
features 
Oncogene 
 
 
 
 
 
Liang et al., 2017 
 
 
 
 
 
Bladder 
cancer 
Upregulated 
 
 
 
miR-200c 
 
 
 
Unknown 
 
 
 
⬆ Cancer stem cells 
clonality and 
self-renewal 
EMT 
Oncogene 
 
 
 
Xu et al., 2018 
 
 
 
Upregulated 
 
 
miR-124 
 
 
AR 
 
 
⬆ Cell proliferation 
⬆ Invasion 
⬆ Migration 
Oncogene 
 
 
Xiong et al., 2017 
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in lung carcinogenesis because it was reported to act as a 
ceRNA on various miRNAs. For instance, in non-small cell 
lung carcinoma (NSCLC), a thorough analysis of XIST 
expression revealed that XIST is overexpressed in non-
small cell lung cancer tissues compared to normal tissues. 
In addition, the high expression of XIST in lung cancer 
tissues and cell lines has been associated with more advanced 
cancer stages and a worse prognosis. Currently, many studies 
point to an essential role of XIST in promoting epithelial-
mesenchymal transition (EMT), as reported by (Li et al., 
2018). In their study, XIST knockdown was sufficient to 
inhibit ZEB2 expression and to abrogate the TGF-β1-induced 
EMT in NSCLC, which translates into pulmonary metastasis 
inhibition in mice mainly by sponging both miR-367 and 
Table 1. Functional characterization of XIST in human cancers (Continued) 
 Cancer type 
 
 
XIST 
expression 
level 
XIST molecular 
target (s) 
 
Downstream 
genes 
 
Effect on cancer 
progression and 
metastasis 
Functional role of 
XIST (oncogene/ 
tumor suppressor) 
References 
 
 
Bladder 
cancer 
Upregulated 
 
 
 
miR-139-5p 
 
 
 
Wnt1 
 
 
 
⬆ Cell growth 
⬆ Metastasis 
Worse patient 
survival 
Oncogene 
 
 
 
Hu et al., 2017 
 
 
 
Cervical 
cancer 
Upregulated 
 
 
 
miR-200a 
 
 
 
Fus 
 
 
 
⬆ Tumor progression 
⬆ Distant metastasis 
⬆ Tumor size 
⬆ FIGO stage 
Oncogene 
 
 
 
Zhu et al., 2018 
 
 
 
Osteosarcoma 
Upregulated 
 
 
 
 
miR-195-5p 
 
 
 
 
YAP 
 
 
 
 
⬆ Cell proliferation 
⬆ Invasion 
⬆ EMT 
⬆ Tumor growth 
Poor clinical prognosis 
Oncogene 
 
 
 
 
Yang et al., 2018 
 
 
 
 
Upregulated 
 
miR-320b 
 
RAP2B 
 
⬆ Cell proliferation 
⬆ Invasion 
Oncogene 
 
Lv et al., 2018 
 
Downregulated 
 
 
 
miR-21-5p 
 
 
 
PDCD4 
 
 
 
⬇ Cell proliferation 
⬇ EMT 
⬇ Invasion 
⬇ Overall survival 
Tumor suppressor 
 
 
 
Zhang and Xia, 
2017 
 
 
Upregulated 
 
EZH2 
 
P21 
 
⬆ Cell proliferation 
⬆ Cell cycle 
Oncogene 
 
Xu et al., 2017a 
 
Nasopharynx 
cancer 
Upregulated 
 
 
 
miR-491-5p 
 
 
 
Notch3 
 
 
 
⬆ Cell proliferation 
⬆ Invasion 
⬆ Tumor growth 
⬇ Apoptosis 
Oncogene 
 
 
 
Cheng et al., 2018 
 
 
 
Upregulated 
 
miR-29c 
 
Unknown 
 
⬆ Cell proliferation 
⬆ Radioresistance 
Oncogene 
 
Han et al., 2017 
 
Upregulated 
 
miR-34a-5p 
 
E2F3 
 
⬆ Cell growth 
Poor patient survival 
Oncogene 
 
Song et al., 2016 
 
 
Fig. 1. Change in the number of publications describing the cancer-
associated role of XIST. Online analysis from the National Library
of Medicine PubMed search using the terms "XIST" and "cancer"
(from Jan. 1 to Dec. 31 as date limitations). 
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miR-141. In support of these findings, Jiang et al. (2018) 
have shown that XIST overexpression promotes NSCLC 
invasion by sponging miR-137 in vitro and promotes tumor 
growth in vivo as a result of PXN upregulation, a focal 
adhesion-associated protein that boosts cell migration and 
mobility. Consistently, the knockdown of XIST suppresses 
cell proliferation and TGF-β1-induced EMT in NSCLC by 
sponging miR-137, which induces an aberrant activation of 
Notch (Wang et al., 2018). In line with the above findings, 
the modulation of miR-186-5p by XIST boosts lung cancer 
cell proliferation and invasion (Wang et al., 2017a). On the 
other hand, Zhang et al. (2017) successfully identified that 
XIST is a negative regulator of Bcl-2 through reciprocal re- 
pression between it and miR-449a. Moreover, a trend for the 
increased oncogenic expression of XIST has been observed 
in NSCLC. Consequently, Xu et al. (2017b) showed that 
the expression of miR-374a was abolished by XIST acting 
as ceRNA, which was found to be the reason for the upregu- 
lation of LARP1, an RNA-binding protein that controls the 
5'-terminal oligopyrimidine tract (TOP) mRNA translation 
as a key regulator of the mTOR pathway. In addition, XIST 
has been shown to be involved in the epigenetic regulation in 
NSCLC by interacting with histone modifier such as En- 
hancer of zeste homolog 2 (EZH2) to suppress the transcrip- 
tion of the KLF2 gene by enhancing its binding to the KLF2 
promoter (Fang et al., 2016). Notably, the strong involvement 
of XIST in autophagy has been demonstrated by Sun et al. 
(2017b), as XIST knockdown sensitized NSCLC cells to 
chemotherapy by upregulating miR-17, which targets the 
3'-untranslated region of ATG7. Concomitantly, the lncRNA 
XIST bolsters the resistance of human lung adenocarcinoma 
cells to cisplatin by functioning as a ceRNA to suppress 
let-7i, which promotes its downstream target BAG-1, an 
anti-apoptotic protein shown to interact with BCL-2 (Sun 
et al., 2017a). In agreement with the above findings, XIST 
targets miR-140, which blocks iASPP oncogene expression 
in human lung cancer (Tang et al., 2017). 
Colorectal and Gastric cancer 
Several recently published studies have examined the 
alterations affecting XIST in colon cancer. Notably, the inter- 
action of XIST with several miRNAs has been emphasized 
in colorectal and gastric cancer. For instance, XIST has been 
reported to be a miR-185 sponge that regulates TGF-β1. 
Hence, XIST seems to play an oncogenic role in gastric 
cancer as demonstrated by Zhang et al. (2018). Moreover, 
according to a study conducted by Sun et al. (2018a), XIST 
sponged miRNA-34a. The endogenous suppressive effect 
of XIST promoted the proliferation and invasion of colon 
cancer cells by Wnt/β-catenin signaling activation, which 
leads to the upregulation of c-Myc and cyclin D1 (Sun et 
al., 2018b). On the other hand, XIST has been shown to 
boost EZH2 by targeting the miR-137-EZH2 axis to foster 
the tumor metastasis of colorectal cancer cells (Liu et al., 
2018a). Consistent with these results, the lncRNA XIST has 
been proposed as a novel predictive marker for patients with 
digestive system tumors, as the high expression of XIST 
was linked with unfavorable overall survival and a poor 
prognosis (Liu et al., 2018b). In addition, Ma et al. (2017b) 
have highlighted the cell cycle regulatory role of XIST in 
gastric cancer where it promotes G1-S cell cycle progression, 
which has an anti-apoptotic effect and a growth-boosting 
effect. This effect is mediated through sponging the miR-497 
that suppress its downstream target, metastasis-associated 
in colon cancer 1 (MACC1). Other evidence published by 
Chen et al. supports previous findings that stipulate that the 
long non-coding RNA XIST regulates EMT and metastasis 
in colorectal cancer, as the knockdown of XIST significantly 
upregulated the expression of miR-200b-3p that targets E-
box-binding homeobox 1 (ZEB1), which has a contributing 
role in metastasis and cancer invasiveness (Chen et al., 2017). 
These findings are concordant with those of Song et al. 
(2017) that stipulate that miR-132-3p is sponged by XIST, 
which is a direct target of Mitogen-Activated Protein Kinase 
1 (MAPK1), which promotes colorectal cancer (CRC) sur- 
vival and proliferation. It should be noted that XIST promotes 
resistance to chemoresistance drugs such as 5-fluorouracil 
(5-FU) in colorectal cancer by promoting thymidylate syn- 
thase, a crucial enzyme in the early stages of DNA synthesis 
and a direct target of 5-FU (Xiao et al., 2017). It was also 
revealed by Chen et al. (2016) that XIST modulates EZH2 
expression by sponging miR-101, a negative regulator of 
EZH2. 
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Liver cancer 
In contrast to what has been observed in lung cancer and 
gastric cancer, in which the lncRNA XIST serves as an onco- 
gene, the findings on XIST and liver cancer are seemingly 
conflicting. Hence, additional studies are urgently needed 
to reconcile these conflicting findings. For instance, Kong 
et al. (2018) have shown that the aberrant overexpression 
of XIST in hepatocellular carcinoma cells promoted the 
proliferation and invasion of liver cancer cells, where XIST 
might act as a sponge of miR-194-5p, which derepresses 
MAPK1. However, Chang et al. (2017) reported that the 
induced overexpression of XIST in hepatocellular carcinoma 
(HCC) cells abrogates invasion, migration, and proliferation 
compared to those in control cells. This effect is facilitated 
through the XIST-mediated epigenetic regulation of miR- 
181a, a well-known inhibitor of phosphatase and tensin 
homolog (PTEN). In keeping with this previous finding, 
Mo et al. (2017) have found a negative correlation between 
XIST and miR-139-5p and revealed that the reciprocal in- 
hibition between miR-139-5p and XIST promoted pyruvate 
dehydrogenase kinase 1 (PDK1), a direct target of miR- 
139-5p and an AKT activator at T308 residue. Consistent 
with the findings of the Mo et al. (2017) and Ma et al. 
(2017a) reported that XIST and its activator JPX lncRNA 
were downregulated in patients with HCC and that JPX/ 
XIST upregulation in patients with hepatocellular carcinoma 
is associated with a good prognosis. In addition, Zhuang et al. 
(2016) have just confirmed the aforementioned findings by 
claiming that miR-92b, a microRNA with an oncogenic role 
in hepatocellular carcinoma, is targeted by XIST, thus ham- 
pering the miR-92a inhibiting effect on Smad7, a TGF-β 
type 1 receptor antagonist with a tumor suppressor role. 
Breast cancer 
Zheng et al. (2018) have shown that XIST is a cell growth 
and metastasis inhibitor in breast cancer. This role seems 
irrevocably linked to its sponge activity of miR-155, which 
directly targets CDX1, an inducer of genes related to cell 
adhesions in angiogenesis and EMT. Of particular interest, a 
study conducted by Huang et al. (2016) showed that a sig- 
nificant XIST reduction in breast tumor samples and breast 
cancer cell lines was associated with JPX downregulation 
and aberrant AKT activation. Moreover, XIST knockdown 
diminished PHLPP1 expression, which plays an AKT phos- 
phatase role. On the other hand, as the development of 
resistance to chemotherapy remains an issue in breast cancer 
as well as many other cancers, Schouten et al. (2016) investi- 
gated the impact of XIST and tumor suppressor p53-binding 
protein 1 (53BP1) expression on recurrence-free survival, 
disease-free survival, and overall survival in patients with 
breast cancer carrying the BRCA1 mutation and showed 
that low 53BP1 and high XIST expression are linked to a 
poor outcome following high-dose alkylating chemotherapy. 
Glioma 
Recently published data provide evidence of the oncogenic 
role of XIST in human glioma, whereby XIST has onco- 
genic activity by targeting miR-137, based on the findings 
of Wang et al. (2017b). Indeed, XIST, by sponging miR- 
137, enhanced Rac1 expression, a pleiotropic regulator of 
many cellular processes such as the cell cycle, differentiation, 
invasion, and motility. Notably, in the case of high-grade 
glioma whereby the use of a combination of chemotherapy 
and radiotherapy results in a clear improvement, although it 
remains limited because of recurrence, XIST has been shown 
to boost the chemoresistance of glioma cells to temozolomide 
(TMZ) by direct binding to miR-29c. This was confirmed by 
knockdown of XIST, which significantly increased miR-29c 
expression but suppressed the expression of MGMT, SP1, 
and MSH6, which are considered important DNA mismatch 
repair (MMR) regulators (Du et al., 2017). On the other hand, 
a causal relationship between XIST expression and glioma 
angiogenesis and blood-tumor barrier permeability has been 
established by Yu et al. (2017), who demonstrated that 
miR-137 is a direct target of XIST, which inhibits FOXC1 
and tight junction protein ZO-2 in normal cells. Hence, 
XIST knockdown facilitates the delivery of chemothera- 
peutic agents through the blood-tumor barrier and abrogates 
angiogenesis by reducing the promoter activity of CXCR7. 
Alternatively, the sponging effect exerted by XIST on miR- 
429 has been proposed by Cheng et al. (2017) as a promoter 
of glioma angiogenesis and tumorigenicity. In line with the 
above findings, Yao et al. (2015) have elucidated the cor- 
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relation between XIST expression and human glioblastoma 
stem cells by demonstrating the existence of reciprocal re- 
pression between miR-152 and XIST, which bind to each 
other. Indeed, XIST knockdown promoted the expression 
of miR-152, which triggered apoptosis and hindered glioma 
stem cell proliferation, migration, and invasion as well. 
Pancreas cancer 
Current studies on XIST and pancreas cancer have unani- 
mously agreed that XIST exerts an oncogenic function in 
pancreatic cancer. It is believed that the knockdown of 
XIST in pancreatic cancer cells induces apoptosis, reduces 
proliferation, and inhibits migration and invasion, as sup- 
ported by the findings of Sun et al. (2018a) whereby the 
complementary base pairing between XIST and miR-34a-5p, 
a well-known tumor suppressor, hampered its expression. 
Therefore, promotes pancreatic cancer progression. In sup- 
port of this conclusion, Wei et al. (2017) investigated the 
correlation between XIST and miR 133a and found out that 
XIST negatively regulated miR-133a and that miR-133a 
downregulation imposed by XIST boosted EGFR expres- 
sion as a result of liberating the EGFR 3'-UTR micro-RNA 
response elements. Moreover, XIST has been reported to 
act as a promoter of human pancreatic carcinoma by target- 
ing miR-140 and miR-124m, which both target endogenous 
iASPP and CDK1, two important anti-apoptotic proteins 
(Liang et al., 2017). 
Bladder cancer 
Current studies on lncRNA XIST suggest that XIST has 
an oncogenic role in bladder cancer. While several reports 
have demonstrated the overexpression of XIST in human 
bladder tissues, which correlated with a poor prognosis, a 
recent study by Xu et al. (2018) points to a link between 
XIST expression and stemness, as the knockdown of XIST 
in bladder cancer cells dramatically abrogated self-renewal 
and clone formation efficiency. This effect seems to be medi- 
ated through inhibiting miR-200c which is a tumor suppres- 
sor that suppresses growth and EMT in bladder carcinoma 
(Xu et al., 2018). In keeping with these findings, Xiong et 
al. (2017) have confirmed the interaction between XIST 
and miR-124. Mechanistically, the interaction between XIST 
and miR-124 abrogated the binding capability of miR-124 
to the androgen receptor (AR) 3'-UTR region and thus pro- 
moted AR expression, which boosts bladder cancer progres- 
sion. In conjunction with previous findings, Hu et al. (2017) 
provided support for the XIST lncRNA sponge hypothesis, 
as they concluded that XIST knockdown substantially in- 
hibited bladder cancer growth and metastatic potential in 
vitro and tumor size in vivo considering that miR-139-5p 
targets Wnt1, a proto-oncogene implicated in oncogenesis, 
embryogenesis, and cell fate determination. 
Cervical cancer 
In cervical after cancer, the increased expression of XIST 
has been associated with a better overall survival (OS) in 
patients with cervical squamous cell carcinoma receiving 
chemoradiation therapy, as the 4-year overall survival rate 
was 87.1% in patients highly expressing XIST as opposed 
to 54.4% in patients with low XIST expression as reported 
by Kobayashi et al. (2016). In an attempt to investigate the 
sponge function of XIST in cervical cancer, Zhu et al. (2018) 
carried out a loss-of-function assay to determine which 
miRNA is the interaction partner of XIST. Interestingly, miR- 
200 was inhibited by XIST, which induced the upregulation 
of RNA-binding protein Fused in Sarcoma/Translocated in 
Sarcoma (FUS/TLS), an important oncogenic protein. 
Osteosarcoma 
There is an urgent need to unravel the function of XIST 
in osteosarcoma. Yang et al. (2018) examined the hypoth- 
esis that XIST is a miRNA sponging lncRNA in osteogenic 
sarcoma by analyzing the interaction of XIST with its down- 
stream target miR-195-5p using dual-luciferase assays and 
bioinformatics prediction tools. Importantly, XIST was found 
to be a direct inhibitor of miR-195p, which decreased the 
binding between the YAP 3'-UTR and miR-195-5p. Hence, 
the YAP promoter was activated, boosting YAP expression 
in osteosarcoma cells. Another study conducted by Li et al. 
(2017) highlighted that XIST overexpression in osteosarcoma 
has a correlation with advanced tumor size, advanced clinical 
stage, distant metastasis progression, and thus a poor pro- 
gnosis in patients with osteosarcoma. Additionally, XIST 
overexpression promoted osteosarcoma cell proliferation. 
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In parallel, another interesting finding by Lv et al. (2018) 
suggested that XIST targeted miR-320b, thus promoting 
osteosarcoma proliferation and invasion by upregulating ras-
related protein RAP2B. On the contrary, XIST has been 
reported by Zhang and Xia (2017) to play a tumor sup- 
pressor role in osteosarcoma by endogenously competing 
with miR-21-5p, thus upregulating PDCD4, an apoptosis-
inducing protein. On another note, Xu et al. (2017a) have 
reported that XIST overexpression in OS tissues impedes 
p21 expression epigenetically. This is mediated by XIST 
binding to EZH2, the main member of the PRC2 complex. 
Nasopharyngeal cancer 
As detailed in this review, many studies have shown that 
XIST is an endogenous competitor of several tumor sup- 
pressor miRNAs in various tumors, which promotes tumor 
proliferation, resistance, and metastasis. Nasopharyngeal car- 
cinoma is no exception, as the knockdown of XIST mitigated 
nasopharyngeal carcinoma advancement by upregulating 
miR-491-5p, which suppressed Notch3 expression in naso- 
pharyngeal carcinoma cells (Cheng et al., 2018). Moreover, 
Han et al. (2017) elucidated that miR-29c downregulation 
by XIST enhanced the radioresistance of nasopharyngeal 
carcinoma cells, thus demonstrating that the XIST/miR-29c 
axis might be promising for overcoming nasopharyngeal 
carcinoma resistance to radiotherapy. Song et al. (2016) 
clarified the oncogenic function of XIST in nasopharyngeal 
carcinoma by showing the involvement of XIST in upregu- 
lating E2F3 through miR-34a-5p sponging. 
 
CONCLUSION 
 
As it has been almost three decades since the discovery 
of XIST, the oncogenic role of XIST is systematically being 
clarified. There is a substantive evidence pertaining to the 
oncogenic overexpression of XIST across several tumor 
tissues in conjunction with its ceRNA function, which in- 
volves a plethora of miRNA targets that differ in a tissue- 
and context-dependent manner. Within this framework, sig- 
nificant progress has been achieved in identifying the inter- 
acting partners of XIST miRNA in vitro and in vivo. However, 
further studies in other cancer types such as leukemia are 
urgently needed, and several questions that are essential to 
understand the oncogenic functions of XIST remain un- 
answered, and thus could open new research avenues. 
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